Neoadjuvant pamiparib plus abiraterone and androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: an open-label, single-arm, phase 2 study

<p>Prostate Cancer and Prostatic Diseases, Published online: 26 December 2025; <a href="https://www.nature.com/articles/s41391-025-01068-2">doi:10.1038/s41391-025-01068-2</a></p>Neoadjuvant pamiparib plus abiraterone and androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: an open-label, single-arm, phase 2 study